A Phase 3 interventional study of sirolimus and cyclosporine in Graft vs Host Disease and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-28.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing sirolimus in Graft vs Host Disease — 2 open to participants now, 5 under way, none of them phase 3. Sirolimus · Graft vs Host Disease.
Among the 35 studies testing sirolimus in Graft vs Host Disease, this one is the 11th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 3, and was the 11th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →2 of the 35 studies testing sirolimus in Graft vs Host Disease are open now. Recruiting first, the newest first:
Peking University People's Hospital
Ages 14+
Peking University People's Hospital
Ages 14+
Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 23 · Phase 3 6 · Phase 4 2
First in 1996; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 34 across the 34 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
Pfizer has 7 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing sirolimus in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07796620Peking University People's HospitalSirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing sirolimus in Graft vs Host Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and corticosteroids versus transplanted patients treated with cyclosporine, mycophenolate and corticosteroids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sirolimus + Daclizumab + Mycophenolate + Corticosteroids
Drug: sirolimus · Drug: mycophenolate mofetil · Drug: corticosteroids · Drug: daclizumab
Cyclosporine + Mycophenolate + Corticosteroids
Drug: cyclosporine · Drug: mycophenolate mofetil · Drug: corticosteroids
15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
Mean Creatinine Clearance Rate
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.
Time frame: 12 months
Number of Patients With Acute Rejection
The diagnosis of acute rejection was made via kidney biopsy (Banff criteria). The Banff criteria are standardized diagnostic categories based on histological assessments (e.g., cell types and distributions). Biopsy was performed before initiation of anti-rejection therapy, or at least within 24 hours of the start of therapy.
Time frame: 3 and 12 months
Patient and Graft Survival
Graft survival is measured by graft loss which is defined as removal of the transplant.
Time frame: 12 months
Mean Creatinine Clearance Rate - 3 Months
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.
Time frame: 3 months
Patients were recruited in Sweden from November 2004 to September 2007.
| Milestone | Sirolimus | Cyclosporine (CsA) |
|---|---|---|
| Started | 31 | 30 |
| Completed | 10 | 16 |
| Not completed | 21 | 14 |
| Withdrew: Adverse event | 9 | 9 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Lack of efficacy | 3 | 1 |
| Withdrew: Procedural complications | 9 | 3 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.
| ml/min | Sirolimus | Cyclosporine (CsA) |
|---|---|---|
| Mean Creatinine Clearance Rate | 56.800 ± 21.522 | 53.449 ± 15.497 |
The diagnosis of acute rejection was made via kidney biopsy (Banff criteria). The Banff criteria are standardized diagnostic categories based on histological assessments (e.g., cell types and distributions). Biopsy was performed before initiation of anti-rejection therapy, or at least within 24 hours of the start of therapy.
| patients | Sirolimus | Cyclosporine (CsA) |
|---|---|---|
| 3 months | 3 | 9 |
| 12 months | 5 | 10 |
Graft survival is measured by graft loss which is defined as removal of the transplant.
| patients | Sirolimus | Cyclosporine (CsA) |
|---|---|---|
| Patient survival | 31 | 29 |
| Graft loss | 0 | 3 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.
| ml/min | Sirolimus | Cyclosporine (CsA) |
|---|---|---|
| Mean Creatinine Clearance Rate - 3 Months | 55.200 ± 22.403 | 51.878 ± 15.974 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sirolimus | — | — | — |
| Cyclosporine (CsA) | — | — | — |
| Event | Sirolimus | Cyclosporine (CsA) |
|---|---|---|
| Kidney transplant rejectionImmune system disorders | 4/31 | 8/30 |
| LymphoceleBlood and lymphatic system disorders | 4/31 | 6/30 |
| Cytomegalovirus infectionInfections and infestations | 3/31 | 5/30 |
| PneumoniaInfections and infestations | 3/31 | 4/30 |
| Blood creatinine increasedInvestigations | 1/31 | 3/30 |
| Urinary tract infectionInfections and infestations | 3/31 | 0/30 |
| Wound complicationInjury, poisoning and procedural complications | 3/31 | 0/30 |
| Renal impairmentRenal and urinary disorders | 3/31 | 1/30 |
| AnemiaBlood and lymphatic system disorders | 2/31 | 2/30 |
| Transplant rejectionImmune system disorders | 0/31 | 2/30 |
| Event | Sirolimus | Cyclosporine (CsA) |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 15/31 | 17/30 |
| NauseaGastrointestinal disorders | 7/31 | 10/30 |
| Adema peripheralGeneral disorders | 10/31 | 9/30 |
| ArrhythmiaCardiac disorders | 9/31 | 6/30 |
| Kidney transplant rejectionImmune system disorders | 3/31 | 8/30 |
| OedemaGeneral disorders | 8/31 | 4/30 |
| Urinary tract infectionInfections and infestations | 8/31 | 4/30 |
| LeukopeniaBlood and lymphatic system disorders | 4/31 | 7/30 |
| ConstipationGastrointestinal disorders | 4/31 | 7/30 |
| DiarrheaGastrointestinal disorders | 7/31 | 2/30 |
| Age Continuous(years) | Sirolimus | Cyclosporine (CsA) | Total |
|---|---|---|---|
| Mean | 61.00 ± 10.00 | 59.60 ± 10.10 | 60.31 ± 10.04 |
| Sex: Female, Male(Participants) | Sirolimus | Cyclosporine (CsA) | Total |
|---|---|---|---|
| Female | 9 | 13 | 22 |
| Male | 22 | 17 | 39 |
The record gives a start of Nov 2004, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sirolimus · Daclizumab
Wyeth is now a wholly owned subsidiary of Pfizer →